CD4 and leukemia: Furthermore, by comparing the potential stimulation of CD8+ CTL responses and anti-leukemia immunity derived from LEX-CD8086 and CD4+ TLEX-CD8086 cell vaccine, we proved that CD4+ TLEX-CD8086 cells induced stronger LAA-specific CD8+ CTL responses and antitumor immunity than LEX-CD8086, possibly as a result of lacking APC mediation and less Th1 cytokine secretion in LEX-CD8086.